Legend Biotech Business Summary

Legend Biotech Corp (LEGN) is a commercial-stage biopharmaceutical leader specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies. The company’s primary revenue model is centered on a 50/50 global profit-sharing collaboration with Janssen Biotech (a Johnson & Johnson subsidiary) for its flagship product, CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for multiple myeloma. Business segments are bifurcated into Collaboration Revenue, driven by CARVYKTI’s rapid expansion into second-line treatment settings, and License Revenue, derived from milestone-based partnerships such as its DLL3-targeting CAR-T agreement with Novartis. As of early 2026, the company is transitioning toward company-wide operating profitability, supported by a global manufacturing network capable of delivering over 10,000 annual doses. Legend Biotech competes directly with Bristol Myers Squibb (Abecma), Gilead/Kite Pharma (Yescarta), and Novartis (Kymriah), maintaining a dominant market position in the multiple myeloma sector due to CARVYKTI’s superior efficacy profile and recent label expansions. Originally founded in 2014 as a subsidiary of GenScript Biotech by scientific pioneer Dr. Frank Fan and GenScript Chairman Dr. Frank Zhang, the company is currently led by CEO Dr. Ying Huang, a former Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch with a PhD from Columbia University. The executive suite includes CFO Carlos Santos and President of R&D Dr. Guowei Fang, an accomplished scientist previously with Zymeworks and Pharmacyclics (AbbVie) who holds a PhD from the University of Colorado and completed postdoctoral training at Harvard Medical School. The board of directors was recently strengthened in early 2026 with the appointments of Robin Meng (Chairman of GenScript) and Gareth Kung as Audit Committee Chair. Legend Biotech remains backed by high-profile institutional investors including GenScript (its largest shareholder), RA Capital Management, and Hudson Bay Capital, reflecting its status as a premier institutional play in the cell therapy space.